Charles River Laboratories Inte
Stocks
Robert Half Inc.
Stocks
Charles River Laboratories vs Robert Half Inc.: Long-Term Investment Analysis
Last updated: June 5, 2026
Summary
This comparison evaluates Charles River Laboratories and Robert Half Inc. as long-term investment options, focusing on financial stability, growth potential, and risk factors. While Charles River offers a robust revenue base within the healthcare sector, Robert Half presents a more stable profit margin and dividend yield, making each suitable for different investor profiles.
Key Differences at a Glance
| Aspect | Charles River Laboratories Inte | Robert Half Inc. | Winner |
|---|---|---|---|
| Market Capitalization | Approximately $8.95 billion | $3.23 billion | Charles River Laboratories Inte |
| Profit Margin | -4.585% | 2.43% | Robert Half Inc. |
| Dividend Yield | None | 7.98% | Robert Half Inc. |
| Beta (Volatility Measure) | 1.446 | 0.792 | Robert Half Inc. |
| Price-to-Earnings (PE) Ratio | PE ratio not available (negative EPS) | 24.31 | Robert Half Inc. |
Market Capitalization: Charles River Laboratories' larger market cap indicates a more established presence and greater long-term stability within healthcare stocks, potentially providing more resilience during market downturns.
Profit Margin: Robert Half’s positive profit margin suggests consistent profitability, an essential factor for long-term investors seeking stable returns, whereas Charles River is currently operating at a loss.
Dividend Yield: Robert Half offers a high dividend yield of nearly 8%, making it attractive for income-focused long-term investors, unlike Charles River, which does not currently pay dividends.
Beta (Volatility Measure): Robert Half’s lower beta indicates less stock price volatility, making it a potentially safer long-term investment during economic fluctuations compared to the more volatile Charles River.
Price-to-Earnings (PE) Ratio: Robert Half’s PE ratio of 24.31 reflects expected growth and profitability, whereas Charles River’s negative EPS indicates current losses, which could be a risk factor for long-term growth.
Detailed Analysis
Charles River Laboratories operates within the Diagnostics & Research industry of the Healthcare sector, with a market capitalization of approximately $8.95 billion and revenue nearing $4.03 billion. Despite its impressive revenue, the company is currently experiencing a loss with an EPS of -3.71 and a negative profit margin of -4.58%. Its beta of 1.446 suggests it is more volatile than the broader market, posing a higher risk for long-term investors seeking stability. The stock price has ranged from a 52-week low of $140.78 to a high of $228.88, reflecting significant price swings over the past year. Its forward PE of around 15 indicates moderate valuation, but the lack of dividends and ongoing losses could hinder long-term income growth.
In contrast, Robert Half Inc. is a leader in Staffing & Employment Services within the Industrials sector, with a market cap of approximately $3.23 billion and revenue of about $5.33 billion. The company reports a positive EPS of 1.3, with a profitable margin of 2.43%, demonstrating consistent profitability. Its beta of 0.792 indicates lower volatility, making it more stable in uncertain economic conditions. Notably, Robert Half offers a substantial dividend yield of 7.98%, perfect for investors prioritizing income continuity over time. The stock has traded between $21.83 and $45.67 in the past year, reflecting more stable price behavior. Its PE ratio of approximately 24.31 suggests that the stock is valued for growth, and its steady earnings make it a reliable long-term holding.
Overall, Charles River’s sizable market cap and revenue base are promising for long-term growth within healthcare, but its current losses and lack of dividends introduce risk. Conversely, Robert Half’s profitability, dividend yield, and lower volatility make it a safer long-term investment, especially for income-focused portfolios. The decision hinges on investor preference for growth potential versus income stability, with Robert Half being the more conservative choice for long-term stability and Charles River offering growth prospects in the healthcare sector that might require patience during recovery phases.
Verdict
Robert Half Inc. emerges as the more balanced long-term investment due to its consistent profitability, attractive dividend yield, and lower stock volatility. However, Charles River Laboratories holds long-term growth potential within the healthcare sector, provided it can turn around its current losses. For risk-averse investors prioritizing income, Robert Half is the better choice; for those seeking growth and willing to accept higher volatility, Charles River offers substantial upside.
Who Should Choose What
Choose Charles River Laboratories Inte if...
Investors seeking exposure to the healthcare diagnostics and research industry with a focus on growth potential, despite current losses. Suitable for long-term investors willing to endure volatility for potential future gains.
Choose Robert Half Inc. if...
Investors prioritizing stable income with high dividend yields, lower volatility, and consistent profitability. Ideal for conservative, income-focused long-term portfolios.